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Abstract
Purpose: To compare the effects of resistance training versus passive physical therapy on bone survival in the
metastatic bone during radiation therapy (RT) as combined treatment in patients with spinal bone metastases.
Secondly, to evaluate overall survival and progression-free-survival (PFS) as well as to quantify prognostic factors
of bone survival after combined treatment.
Methods: In this randomized trial 60 patients were allocated from September 2011 until March 2013 into one of
the two groups: resistance training (group A) or passive physical therapy (group B) with thirty patients in each
group during RT. We estimated patient survival using Kaplan-Meier survival method. The Wald-test was used to
evaluate the prognostic importance of pathological fracture, primary site, Karnofsky performance status, localization
of metastases, number of metastases, and cerebral metastases.
Results: Median follow-up was 10 months (range 2–35). Bone survival showed no significant difference between
groups (p = .303). Additionally no difference between groups could be detected in overall survival (p = .688) and
PFS (p = .295). Local bone progression was detected in 16.7 % in group B, no irradiated bone in group A showed a
local progression over the course (p = 0.019). In univariate analysis breast cancer, prostate cancer, and the presence
of cerebral metastases had a significant impact on bone survival in group B, while no impact could be
demonstrated in group A.
Conclusions: In this group of patients with spinal bone metastases we were able to show that guided resistance
training of the paravertebral muscles had no essential impact on survival concomitant to RT. Importantly, no local
bone progression in group A was detected, nevertheless no prognostic factor for combined treatment could be
evaluated.
Trial registration: Clinical trial identifier NCT 01409720. Registered 8 February 2011.
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Background
Spinal bone metastases represent the most frequent site
of skeletal metastasis [1], and two-thirds of all tumor pa-
tients are estimated to develop bone metastases in the
course of their disease [2]. Bone metastases are a major
clinical concern due to severe pain, pathological frac-
tures, spinal cord compression and hypercalcaemia with
a significant decrease of the quality of life (QoL) [3, 4].
Radiotherapy (RT) is the most common treatment
option of bone metastases in advanced tumor disease
[4–6], and is effective in reducing symptoms, increases
subjective well-being, and has minimal side effects [7].
The classification into stable and unstable bone metasta-
ses and pathological fractures are of great clinical rele-
vance regarding mobility and QoL in patients’ palliative
care. Most patients with spinal metastases have a limited
life expectancy [8]. The early initiation of therapy, which
can generally be viewed as being given as palliative
therapy, brings about a significant improvement of the
QoL and appears to prolong the survival time [9]. The
median overall survival varies from 7 to 32 months, de-
pending on significant predictors e.g., Karnofsky per-
formance score (KPS), primary tumor, and the absence
of visceral metastases [8, 10–12]. Previously we showed
that within our study guided resistance training of the
paravertebral muscles could safety be practiced in pallia-
tive patients with stable bone metastases of the vertebral
column; leading to an improved pain score and mobility
as well as reduced fatigue and thereby an enhanced QoL
[13, 14]. Secondary, we were able to show that resistance
training concomitant to RT can improve pain relief, and
improve bone density in the metastasis as a local re-
sponse over a 6-months period [15, 16]. However, in our
recent work, we analyzed the endpoints feasibility, QoL,
local response, and pain of resistance training in patients
with spinal bone metastases under RT until 6 months.
The aim of this analysis was to compare the bone
survival of patients with spinal bone metastases under re-
sistance training versus passive physical therapy concomi-
tant to RT. Secondary endpoints were overall survival,
progression free survival, and to quantify prognostic fac-
tors to bone survival after combined treatment.
Methods
This is a randomized, controlled, two-armed interven-
tion trial. A block randomization approach with block
size 6 was used to ensure that the two groups were bal-
anced. Inclusion criteria were an age of 18 to 80 years,
KPS [17] ≥ 70, written consent to participate, and already
initiated bisphosphonate therapy. The patients were sub-
jected to a staging of their vertebral column within the
context of the computed tomography (CT) designed to
plan the radiation schedule prior to enrolment into the
trial. In this examination metastases were classified as
“stable” or “unstable”. This was diagnosed independently
by a specialist for radiology as well as by a specialist for
orthopedic surgery. The specifications for an unstable
vertebral body were tumor occupancy more than 60 %
of the vertebral body, and pedicle destruction [18]. Only
a metastasis classified by both specialists as “stable” was
suggested eligible for inclusion. After the baseline mea-
surements, the patients with stable bone metastases
were assigned to the respective treatment groups on a
1:1 basis according to the randomization list. Group A
(intervention group, resistance training) and in group B
(control group, passive physical therapy) each consisted
of 30 patients. The primary endpoint was to compare
bone survival between the two groups. Secondary end-
points were to quantify overall survival, progression free
survival (PFS), and prognostic factors for bone survival.
Local bone progression was defined as progressive
treated bone metastasis, while systemic progressive bone
was defined as additional bone metastases to the treated
site. Progressive disease was defined as local progression
and/or systemic progressive bone and/or death. PFS was
the time between first diagnosis or existence of bone
metastases (time equalized to the start of RT) until pro-
gressive disease or death. The progression of bone dis-
ease was estimated by CT scans 3, 6, 12 and 24 months
after RT. The progressive treated bone metastases were
classified by MDA criteria [19]. Bone survival was the
time from first diagnosis or existence of bone metastases
(time equalized to the start of RT) until death, and over-
all survival was the time from first diagnosis of primary
site until death. Bone metastases distant from the irradi-
ated site were not included. Patient-specific data was
documented. The study was approved by the Heidelberg
Ethics Committee (S-316/2011).
Radiotherapy
Radiotherapy was performed in the Department of Radi-
ation Oncology at the University Hospital Heidelberg.
After virtual simulation was performed for treatment
planning, radiotherapy was carried out over a dorsal
photon field of 6MV energy range. Primary target
volume (PTV) covered the specific vertebral body af-
fected as well as the ones immediately above and below.
In group A twenty-four patients (80 %) were treated
with 10 × 3 Gy, three patients (10 %) with 14 × 2.5 Gy,
and three patients (10 %) with 20 × 2 Gy. In group B the
dose fractions for twenty-eight patients (93.3 %) were 10 ×
3 Gy, for one patient (3.3 %) 14 × 2.5 Gy, and for one pa-
tient (3.3 %) 20 × 2 Gy. The median individual dose in all
patients was 3 Gy (range 2–3 Gy), the median total dose
30 Gy (range 20–35 Gy). The individual and total doses
were decided separately for each individual patient, de-
pending on histology, patient’s general state of health,
current staging and the corresponding prognosis.
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Exercise interventions
The interventions commenced on the same day as radio-
therapy and were performed on each day of RT treat-
ment (Monday through Friday) over a 2-week period,
independent of the number of fractions. During the 2-
week RT period, the patients in the resistance training
group (group A) performed the exercises under the
guidance of a trained physiotherapist. The patients were
then instructed to perform all trainings at home three
times per week until the endpoint assessment after 6
months. Self-reported training adherence was registered
in a training diary. The resistance training lasted approx.
30 min, the passive physical therapy (group B) approx.
15 min. Since the site of the bone metastases differed
from patient to patient, three different exercises were
enacted to ensure an even resistance training of the
muscles along the entire vertebral column. A detailed
description of the exercise interventions was published
earlier [16, 20].
Statistical approach
On account of the explorative character of this study it
was not possible to estimate the total number of cases;
with a scheduled number of 30 patients per group, it
will, however, be possible to detect a standardized mean-
value effect of 0.74 with a power of 80 % and an α sig-
nificance level of 5 %. We calculated descriptive p-values
of the corresponding statistical tests comparing the
treatment groups. Wilcoxon u test was used for differ-
ence between groups. We estimated patient survival
using Kaplan-Meier survival method. Patients were cen-
sored on the basis of whether they were alive. The
Wald-test was used to evaluate the prognostic import-
ance of pathological fracture (yes/no), primary site (non-
small cell lung cancer (NSCLC), breast cancer, prostate
cancer, other), KPS (70/>70), localization of metastases
(thoracic/lumbar), number of metastases (1/>1), and
cerebral metastases. The results were reported as sur-
vival times, p-values, hazard ratios including 95 % confi-
dence intervals (CI). For all analysis, a p-value of 0.05 or
less was considered significant. All statistical analyses
were done using SAS software Version 9.3 (SAS Insti-
tute, Cary, NC, USA).
Results
From September 2011 through March 2013, consecu-
tively 80 patients with a histologically confirmed cancer
of any primary and spinal bone metastases of the
thoracic or lumbar segments were considered in the
Department of Radiation Oncology at the University
Hospital Heidelberg. Fifteen patients were excluded due
to unstable metastases, and five patients declined to par-
ticipate in the study. Sixty patients fulfilled the inclusion
criteria and were enrolled into the trial. Groups were
balanced at baseline, and except for visceral metastases
there were no group differences (Table 1). The median
follow-up was 10 months (range 2–35) for both groups.
All surviving patients completed all surveys. Mortality
did not differ between groups.
Bone survival showed no significant difference be-
tween groups (p = 0.303); bone survival after 12 and
24 months was 58 and 42 % in group A, and 51 and
30 % in group B (Fig. 1). Overall survival after 12 and
24 months was 80 and 63 % in group A, and 70 and
57 % in group B respectively (p=0.688; Fig. 2). The
PFS did not differ between groups; mean PFS was
24.3 months in group A and 20.5 months in group B
(p = 0.295; Fig. 3).
Local progression was detected in 16.7 % in group B,
no irradiated bone in group A showed a local progres-
sion over the course (p = 0.019). Progressive disease and
systemic bone progression showed no difference be-
tween groups (p = 0.095 and p = 0.108; Table 2).
In univariate analysis breast cancer (HR 0.103, 95 % CI
0.024–0.442, p = 0.002), prostate cancer (HR 0.160, 95 %
CI 0.050–0.511, p=0.002), and the presence of cerebral
metastases (HR 3.211, 95 % CI 1.063–9.695, p = 0.038)
showed a significant impact on bone survival to group B,
while no impact in group A could be demonstrated
(Table 3).
Discussion
The first results of this novel trial showed that
guided resistance training of the paravertebral mus-
cles can safely be practiced in palliative patients with
stable bone metastases of the vertebral column. Fur-
thermore improved pain and local response, reduced
fatigue and enhanced QoL could be detected within
6 months.
In our current analysis, bone survival, overall sur-
vival, and PFS showed no significant differences be-
tween groups in long-term follow-up. The effect of
resistance training showed an improved local re-
sponse in group A [16], and no local bone progres-
sion at the irradiated bone metastases could be
detected, while in group B 16.7 % of patients ex-
panded a progression in the vertebral body. Never-
theless these data had no impact on PFS. Overall
survival and bone survival showed no differences as
well. We interpreted this result as minor impact of
resistance training. On the one hand, at baseline vis-
ceral metastases were significantly higher in group
A, which represents a prognostic factor for survival
in the literature, on the other hand a positive ten-
dency for group A could be shown in overall sur-
vival and bone survival. Additional small sample size,
and different primary tumor types played a major
role on the assessment. The most prevalent tumors
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were those of breast and prostate [21]. These tumor
entities had an improved bone survival in group B,
but showed no impact in group A. This result
explained itself on account of several additional dis-
tant metastases which were detected in group A col-
lectively. In a study by van der Linden et al.
Table 1 Patient characteristics at baseline
Intervention group A (n = 30) Control group B (n = 30) P-value
n % n %
Age (years)
Mean (SD) 61.3 +/- 10.1 64.1 +/- 10.9 0.304
Gender
Male 14 46.7 19 63.3 0.195
Female 16 53.3 11 36.7
Karnofsky-index (median, range) 80 (70–100) 80 (70–100) 0.114
Primary site
Lung cancer 12 40.0 8 26.6 0.320
Breast cancer 5 16.7 6 20.0 0.542
Prostate cancer 5 16.7 9 30.0 0.156
Melanoma 1 3.3 1 3.3 1.000
Renal cancer 1 3.3 2 6.7 0.875
Other 6 20.0 4 13.4 0.325
Localization metastases 0.717
Thoracic 17 56.7 14 46.7
Lumbar 9 30.0 13 43.3
Thoracic and lumbar 2 6.7 2 6.7
Sacrum 2 6.7 1 3.3
Number metastases 0.257
Mean (range) 1.4 (2–4) 1.7 (1–5)
Solitary 22 73.3 18 60.0
Multiple 8 26.7 12 40.0
Type of metastases 0.781
osteoblast 9 30.0 10 33.3 0.956
osteolytic 21 70.0 20 66.7 0.935
Distant metastases at baseline
Visceral 12 40.0 5 16.7 0.045
brain 3 10.0 4 13.4 0.688
lung 7 23.3 4 13.4 0.320
tissue 8 26.7 6 20.0 0.542
Pathological fractures 6 20.0 9 30.0 0.371
Hormonotherapy 10 33.3 16 53.3 0.118
Immunotherapy 7 23.3 5 16.7 0.519
Chemotherapy 25 83.3 20 66.7 0.136
Neurological deficit 0 0.0 2 6.7 0.150
Orthopedic corset at baseline 7 23.3 5 16.7 0.519
Radiotherapy dose completed (Gy)
single dose (median, range) 3 (2–4) 3 (2–4) 1.000
cumulative dose (median, range) 30 (30–40) 30 (30–40) 1.000
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involving 342 patients with spinal metastases, the
most important prognostic factors were performance
status, metastatic involvement of other organs and
primary site [8]. In the study by Katagiri et al. [22],
primary tumor, performance status, number of bone
metastases, metastatic involvement of other organs
and previous chemotherapy regimens constituted im-
portant prognostic factors among 350 patients with
bone metastases. In a retrospective analysis of 356 pa-
tients, Rades et al. [23] identified that improved sur-
vival was significantly associated with female gender,
an Eastern Cooperative Oncology Group performance
score (ECOG-PS) of 1–2, pre-RT ambulatory status,
the absence of other bone metastases, the absence of
visceral metastases, an interval from cancer diagnosis
to RT of >15 months and slower (>7 days) develop-
ment of motor deficits. Our trial was not able to
demonstrate a survival benefit of resistance training
concomitant to RT, and identified only tumor type
and cerebral metastases as prognostic factors in our
control group. However, the knowledge of prognostic
factors and of the prognosis following bone metastasis
is of critical importance. A paper by Sugiura et al.
[24] considering 118 patients with bone metastases
Group 
months
Fig. 1 Progression free survival of both groups
  Group 
months
Fig. 2 Overall survival of both groups
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showed a 1-year survival rate of 31.6 % and a 2-year
survival rate of 11.3 % for lung cancer. Overall
survival rates of patients with renal cell carcinoma
were described with 74 % after one year [25]. Corres-
pondingly, the survival rates especially differ in the
literature depending on the primary tumor. Based on
the different primary types in our trial, these data are
not comparable.
Bone metastases are among the most serious
problems seen in tumor patients and bone pain,
pathological fractures and neurological deficits can
be life-threatening events [26]. Palliative RT consti-
tutes one of the most important therapeutic options
in these situations. In our recent work, we were able
to demonstrate a benefit in QoL, pain response, local
response, and reduced fatigue for patients after com-
bined treatment with resistance training concomitant
to RT. However, our results showed no differences
in survival. In our opinion, the combined treatment
with resistance training concomitant to RT is a very
effective novel treatment. Future trial designs should
stratify to primary tumor and visceral metastases.
Further limitations of the study were the relatively
small sample size, the variety of primary tumors and
patient conditions, and the exclusion of patients pre-
senting with cervical spine metastases. Among the
strengths of our novel and original study were the
randomized design and long-term follow-up among
palliative patients with spinal bone metastases.
Conclusion
In this group of patients with spinal bone metastases we
were able to show that guided resistance training of the
paravertebral muscles had no essential impact on bone
survival, overall survival, and progression free survival
concomitant to RT. Importantly, the absence of local
bone progression in group A could be detected, never-
theless no prognostic factor for combined treatment was
evaluated.
Group months
Fig. 3 Bone survival of both groups
Table 2 Tumor progression of both groups
Group A Group B
n % n % P-value
Progressive disease 22 73.3 27 90.0 0.095
Local bone progression 0 0.0 5 16.7 0.019
Systemic bone progression 8 26.7 14 46.7 0.108
Table 3 Univariate analysis for prognostic factors of bone survival
Intervention group (n = 30) Control group (n = 30)




1.288 0.371–4.467 0.690 0.833 0.343–2.020 0.686
KPS 0.527 0.216–1.289 0.161 0.872 0.372–2.043 0.752
Localization 0.588 0.209–1.655 0.315 1.166 0.504–2.694 0.720
Number of
metastases
0.602 0.200–1.812 0.366 1.052 0.469–2.360 0.902
Breast cancer 0.230 0.028–1.923 0.175 0.103 0.024–0.442 0.002
NSCLC 2.442 0.834–7.145 0.103 0.968 0.346–2.712 0.951
Prostate cancer 0.950 0.237–3.804 0.942 0.160 0.050–0.511 0.002
Cerebral
metastases
1.529 0.409–5.716 0.528 3.211 1.063− 9.695 0.038
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